Know Cancer

or
forgot password

Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC


N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information

Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC


Inclusion Criteria:



- Lung Cancer patients with non-small cell histology and stage IV disease who are
candidate for erlotinib treatment as first/ second/ third line of treatment

Exclusion Criteria:

- pregnancy

- severe dyspnoea

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Accumulation of 11c-erlotinib in tumors before and after treatment with erlotinib

Outcome Description:

Accumulation of 11c-erlotinib in tumors will be correlated to PFS on erlotinib treatment.

Outcome Time Frame:

From date of inclusion until the date of first documented progression on the erlotinib treatment or date of death, whichever came first, assessed up to 30 months

Safety Issue:

Yes

Principal Investigator

Peter Meldgaard, Ph.D MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Aarhus University Hospital

Authority:

Denmark: The Regional Committee on Biomedical Research Ethics

Study ID:

1-10-72-19-12

NCT ID:

NCT01889212

Start Date:

April 2013

Completion Date:

April 2015

Related Keywords:

  • Lung Cancer
  • Lung Neoplasms

Name

Location